19 September 2018: vol 19 no 15: UK diagnoses, U=U resources, generic PrEP

This issue of HTB leads with impressive and optimistic results from the UK HIV surveillance programme coordinated by Public Health England.

In 2017, HIV diagnoses fell for the second year across all key demographic groups, including by gender, sexuality, race, age and geographic region. The report launch was out of step though with current prevention strategies by still emphasising condom use over TasP and PrEP.

We continue with reports from the AIDS 2018 conference. These include twice-daily dolutegravir to overcome interactions with rifampicin, early TAF data in pregnancy and high rates of unintended pregnancies in African women on ART.

Stop-press ARV news is that generic PrEP can now be used by NHS England. Doravirine has been approved in the US, also in an FDC, and FDA label updates for dolutegravir.